Acadia ve 2. čtvrtletí překonala odhady: EPS činil 18 centů a tržby 308 milionů USD. Firma zároveň zvýšila celoroční výhled tržeb na 1,24–1,30 miliardy USD.
It has been about a month since the last earnings report for Acadia Pharmaceuticals (ACAD - Free Report) . Shares have added about 0.5% in that time frame, outperforming the S&P 500.
But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Acadia due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
ACAD Q2 Earnings and Revenues Beat, '26 View Raised on Product SalesAcadia reported second-quarter 2026 earnings of 18 cents per share, which surpassed the Zacks Consensus Estimate of 6 cents. The company had reported earnings of 16 cents per share in the year-ago quarter.
Revenues of $308 million beat the Zacks Consensus Estimate of $294 million, reflecting a 16% year-over-year increase. Growth was supported by higher marketed product sales.
ACAD's Q2 Earnings in DetailAcadia’s revenues comprise net product sales from its two marketed drugs, Daybue and Nuplazid. Reported revenues increased from $264.6 million in the second quarter of 2025 to $308 million in the reported quarter.
The company’s quarterly performance benefited from continued demand for both products. Daybue growth was supported by the uptake of the recently launched Daybue STIX formulation, while Nuplazid benefited from volume growth and increased new-patient prescriptions.
Acadia's Nuplazid Sales Rise Year Over YearReported net product sales of Nuplazid were $183.2 million in the second quarter of 2026, up 9% from $168.5 million in the year-ago period. The drug is approved in the United States for treating hallucinations and delusions associated with Parkinson’s disease psychosis. Nuplazid sales beat the Zacks Consensus Estimate of $181.5 million.
Management stated that Nuplazid’s growth was primarily volume-driven. New-patient prescriptions increased 20% year over year and reached their highest quarterly level since the first quarter of 2018. Acadia also continued to expand engagement with priority health care providers through its enlarged field force.
ACAD's Daybue Sales Jump on STIX UptakeDaybue reported net product sales of $124.8 million, up 30% from $96.1 million in the second quarter of 2025. Daybue is approved in the United States for treating Rett syndrome in adult and pediatric patients two years of age and older. The reported figure beat the Zacks Consensus Estimate of $111.3 million.
Growth was driven largely by volume and strong uptake of Daybue STIX. Approximately 40% of U.S. Daybue patients were receiving STIX by the end of the quarter. The company also recorded a quarterly high in the number of patients returning to Daybue treatment.
Acadia stated that around 60% of total referrals during the quarter came from treatment-naive patients, while 40% represented returning patients. For STIX specifically, 55% of patients switched from the oral solution, while the remaining 45% were new or returning patients.
Acadia’s Operating Expenses Rise in Q2Research and development (R&D) expenses were $82 million in the second quarter of 2026, up 5% from $78 million in the year-ago period.
Selling, general and administrative (SG&A) expenses increased 20% year over year to $160 million from $134 million. The increase reflected investments in expanding the Nuplazid and Daybue field forces and higher marketing spending to support both brands.
Acadia had cash, cash equivalents and investment securities worth $956 million as of June 30, 2026, compared with $851 million as of March 31, 2026.
Acadia Raises Its 2026 Revenue OutlookFollowing the strong quarterly performance, Acadia raised its total revenue guidance for 2026 to a range of $1.24 billion to $1.30 billion. The previous guidance range was $1.22 billion to $1.28 billion.
The company increased its Daybue global net product sales forecast to $480-$510 million from the prior range of $460-$490 million. The revised outlook reflects strong U.S. demand, uptake of STIX and expected contributions from international markets.
Nuplazid net product sales guidance was maintained at $760-$790 million. Management expects the expanded field force to have a greater impact on Nuplazid’s performance later in the year as sales representatives deepen engagement with targeted physicians.
Acadia now expects R&D expense in the range of $355-$380 million, down from the previous range of $385-$410 million. SG&A expenses continue to be expected between $660 million and $700 million.
How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a upward trend in estimates review.
The consensus estimate has shifted 59.62% due to these changes.
VGM ScoresAt this time, Acadia has a nice Growth Score of B, however its Momentum Score is doing a bit better with an A. However, the stock was allocated a grade of C on the value side, putting it in the middle 20% for this investment strategy.
Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.
OutlookEstimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. Notably, Acadia has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry PlayerAcadia belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Incyte (INCY - Free Report) , has gained 7.5% over the past month. More than a month has passed since the company reported results for the quarter ended June 2026.
Incyte reported revenues of $1.67 billion in the last reported quarter, representing a year-over-year change of +37.7%. EPS of $3.09 for the same period compares with $1.57 a year ago.
For the current quarter, Incyte is expected to post a loss of $3.31 per share, indicating a change of -246.5% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days.
Incyte has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of A.
Acadia získala v EU schválení pro Daybu k léčbě neurobehaviorálních příznaků Rettova syndromu u dospělých a pediatrických pacientů od pěti let věku. Jde o první a jedinou schválenou léčbu pro tuto indikaci.
Key Takeaways Acadia gained EU approval for Daybu, the first and only approved Rett syndrome treatment in the EU.Daybu is approved for neurobehavioral symptoms of Rett syndrome in adults and children aged five and older.The LAVENDER study showed meaningful improvements in Rett syndrome behavior and global impression. Acadia Pharmaceuticals (ACAD - Free Report) announced that the European Commission (EC) has granted marketing authorization for Daybu (trofinetide) to treat neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. The nod marks a major regulatory milestone for the therapy as it is now the first and only treatment approved for this indication in the EU.
The EU approval enables Acadia to expand Daybu’s commercial footprint across all 27 EU member states, as well as Iceland, Liechtenstein and Norway, strengthening the long-term growth potential of its rare disease franchise. As a next step, Acadia will now begin pricing and reimbursement negotiations with relevant national authorities to potentially bring Daybu to patients across the EU.
The EC approval was expected as the advisory committee to the European Medicines Agency adopted a positive opinion in June 2026 recommending the approval of Daybu for Rett Syndrome. It is a rare, neurodevelopmental disorder marked by developmental regression, severe motor impairment and lifelong care needs. The FDA approved trofinetide as the first and only treatment for Rett syndrome in adults and pediatric patients aged two years and older in 2023. The drug is marketed under the brand name Daybue in the United States. Daybue is also marketed (and available) in Canada and Israel for the same indication.
The EC approval is primarily supported by data from the pivotal phase III LAVENDER study, which demonstrated statistically significant and clinically meaningful improvements in key measures of Rett syndrome. The study met its co-primary endpoints, showing benefits on the Rett Syndrome Behavior Questionnaire and the Clinical Global Impression-Improvement scale, indicating that Daybu can improve some of the core neurobehavioral manifestations of the disease that substantially affect patients' daily functioning and caregiver burden.
Year to date, Acadia shares have gained 10.5% compared with the industry’s 11.1% growth.
Image Source: Zacks Investment Research
ACAD's Marketed Drugs Expected to Aid GrowthAcadia’s long-term growth is anchored by its two marketed products, Nuplazid and Daybue. The company continues to target approximately $1.7 billion in combined annual net sales by 2028, including roughly $1 billion for Nuplazid and $700 million for Daybue.
Nuplazid is the first and only FDA-approved treatment for hallucinations and delusions associated with Parkinson’s disease psychosis in the United States. The drug enjoys patent protection in the United States until 2038, giving it a long runway for revenue generation by protecting against generic erosion. In the first half of 2026, Nuplazid generated $350.1 million in net product sales, up 7% from the year-ago period. The increase was primarily driven by higher unit sales, highlighting continued underlying demand for the drug.
Since its launch in 2023, Daybue has witnessed encouraging sales uptake. The therapy generated $226 million in net product sales in the first half of 2026, up 25% year over year, with the increase primarily reflecting higher unit sales. The EU approval of the drug is expected to further boost sales in the upcoming quarters.
Meanwhile, Daybue STIX, a dye- and preservative-free powder formulation of trofinetide, was broadly launched in the United States in the second quarter of 2026. The formulation provides patients and caregivers greater flexibility while maintaining the same efficacy and safety profile as the original oral solution. Its strong uptake contributed to Daybue’s 30% year-over-year sales growth in the second quarter.
Overall, Acadia’s commercial portfolio remains on a solid growth trajectory. Following second-quarter results, the company raised its 2026 Daybue sales projection to $480-$510 million from the previous guided range of $460-$490 million while maintaining Nuplazid sales guidance of $760-$790 million.
ACAD's Zacks Rank & Stocks to ConsiderAcadia currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Amneal Pharmaceuticals (AMRX - Free Report) , Repligen (RGEN - Free Report) and AC Immune (ACIU - Free Report) . AMRX and RGEN currently sport a Zacks Rank #1 (Strong Buy) each, while ACIU carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, earnings estimates for Amneal Pharmaceuticals have increased from $1.00 to $1.02 for 2026. Over the same period, earnings estimates increased from $1.12 to $1.21 for 2027. AMRX shares have risen 42.1% year to date.
Amneal Pharmaceuticals beat earnings in each of the trailing four quarters, delivering an average surprise of 32.82%.
Over the past 60 days, estimates for Repligen’s 2026 earnings per share have risen from $1.99 to $2.06, while estimates for 2027 have increased from $2.57 to $2.61. RGEN shares have gained 10.6% year to date.
Repligen’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 16.80%.
Over the past 60 days, estimates for AC Immune’s 2026 loss per share have narrowed from 84 cents to 60 cents. Over the same period, earnings estimates for 2027 remained unchanged at 17 cents. ACIU shares have lost 7.7% year to date.
AC Immune’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 33.25%.
ACADIA Pharmaceuticals čeká na data fáze II k remlifanserinu v Alzheimerově psychóze v září až říjnu. Firma zároveň rozšiřuje komerční dosah DAYBUE a NUPLAZID.
Acadia Pharmaceuticals: A Mid-Cap Biotech Making Large MovesACADIA Pharmaceuticals NASDAQ: ACAD outlined commercial expansion plans for its marketed therapies, DAYBUE and NUPLAZID, while highlighting upcoming clinical data for remlifanserin in Alzheimer’s disease psychosis during a discussion hosted by Canaccord Genuity.
Thomas Garner, Acadia’s chief commercial officer, said the company’s commercial strategy has centered on disease education, targeted outreach to healthcare providers and focused execution in both Parkinson’s disease psychosis and Rett syndrome.
Get ACADIA Pharmaceuticals alerts:
NUPLAZID Growth Strategy Garner said NUPLAZID, Acadia’s treatment for Parkinson’s disease psychosis, has continued to gain traction. New-to-brand prescriptions rose 20% year over year in the most recent quarter, he said.
The company has focused on raising awareness that hallucinations and delusions can occur during the course of Parkinson’s disease, while also educating healthcare providers about treatment options. Garner said Acadia estimates that about 1 million people in the U.S. are living with Parkinson’s disease and that roughly half may experience hallucinations and delusions during their disease course.
Acadia’s “More to Parkinson’s” awareness campaign, involving actor Ryan Reynolds, has contributed to a threefold increase in awareness of Parkinson’s disease psychosis among people living with Parkinson’s disease over the past two to three years, according to Garner.
To expand NUPLAZID’s reach, Acadia increased its sales force by roughly 40% earlier this year. The expansion increased the number of healthcare providers targeted by the company from approximately 5,000 to 6,000 to roughly 10,000 to 10,500, Garner said.
Garner said new treatments entering the broader Parkinson’s disease market could help improve disease awareness and diagnosis, potentially supporting demand for therapies addressing psychosis.
DAYBUE Formulation and Persistence DAYBUE, Acadia’s treatment for Rett syndrome, launched in 2023 and is the first and only approved treatment for the condition, according to Garner. Acadia estimates that about 6,000 people in the U.S., primarily young girls, are living with Rett syndrome.
Long-term patient persistence remains a central commercial focus. Garner said 12-month persistence is above 50% to 55%, while approximately 50% of patients remain on treatment at 18 months. He added that 70% of current DAYBUE patients have been receiving therapy for more than 12 months.
The company recently introduced DAYBUE STIX, a powder formulation that can be mixed with a non-dairy liquid. Garner said the formulation removes certain excipients contained in the earlier oral-solution version and may help Acadia reach treatment-naive patients as well as patients who previously discontinued DAYBUE.
In the second quarter, 60% of DAYBUE business came from the oral solution and 40% came from STIX. In June alone, however, 60% of prescriptions were for STIX, suggesting the newer formulation could become the leading form of the franchise over time, Garner said. He noted that some patients may remain on the oral solution because of the complexity of Rett syndrome and caregiver preferences.
Acadia also sees an opportunity to reengage approximately 1,000 Rett syndrome patients who previously tried and later stopped DAYBUE.
European and Japanese Expansion Garner said Acadia recently received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use for DAYBUE and is preparing for a European Commission decision. The company plans to launch first in Germany after an EC decision and to submit pricing and reimbursement dossiers in additional priority markets.
Acadia estimates there are between 8,000 and 12,000 people living with Rett syndrome in the European Union, compared with about 6,000 in the U.S. Garner said the European opportunity is larger in patient numbers, though pricing and access conditions will vary by country.
The company is also conducting a DAYBUE trial in Japan. Garner said Acadia is evaluating a partnership-based approach to bringing the treatment to Japanese patients.
Pipeline and Business Development Acadia expects Phase II data for remlifanserin in Alzheimer’s disease psychosis in the September-to-October timeframe. Garner described the indication as a large commercial opportunity, estimating that 30% of the 7 million to 7.5 million people currently living with Alzheimer’s disease in the U.S. may develop psychosis.
He said Acadia believes remlifanserin could be differentiated by a profile suited to elderly patients with complex medical needs, though he emphasized that the company must first see how the data develop.
Al Kildani, Acadia’s senior vice president of investor relations and corporate communications, said the company also has a Phase II trial of remlifanserin in Lewy body dementia underway and expects Phase II data for ACP-211 in major depressive disorder in the latter part of next year.
Garner said Acadia has close to $1 billion in cash and is evaluating business-development opportunities ranging from near-term commercial assets to additions that could strengthen its mid-stage pipeline. He said the company is not required to pursue a transaction and intends to be selective about potential deals.
About ACADIA Pharmaceuticals (NASDAQ:ACAD)ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA's research centers concentrate on conditions with significant unmet medical needs, including Parkinson's disease psychosis, Alzheimer's disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.
The company's flagship product, NUPLAZID® (pimavanserin), received U.S.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Should You Invest $1,000 in ACADIA Pharmaceuticals Right Now?Before you consider ACADIA Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ACADIA Pharmaceuticals wasn't on the list.
While ACADIA Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
ACADIA Pharmaceuticals Inc. (ACAD) Q2 2026 Earnings Call August 4, 2026 4:30 PM EDT
Company Participants
Albert Kildani - Senior Vice President of Investor Relations & Corporate Communications
Catherine Owen Adams - CEO & Director
Thomas Garner - Executive VP & Chief Commercial Officer
Elizabeth Thompson - Executive VP and Head of Research & Development
Mark Schneyer - Executive VP & CFO
Conference Call Participants
Tessa Romero - JPMorgan Chase & Co, Research Division
Ritu Baral - TD Cowen, Research Division
Ashwani Verma - UBS Investment Bank, Research Division
Marc Goodman - Leerink Partners LLC, Research Division
Tazeen Ahmad - BofA Securities, Research Division
Yigal Nochomovitz - Citigroup Inc., Research Division
Malcolm Hoffman - BMO Capital Markets Equity Research
Sean Laaman - Morgan Stanley, Research Division
Nevin Varghese - RBC Capital Markets, Research Division
Sumant Kulkarni - Canaccord Genuity Corp., Research Division
Guofang Li - Wolfe Research, LLC
David Hoang - Deutsche Bank AG, Research Division
Ananda Ghosh - H.C. Wainwright & Co, LLC, Research Division
Uy Ear - Mizuho Securities USA LLC, Research Division
Julian Hung - Stifel Nicolaus Canada Inc., Research Division
Presentation
Operator
Ladies and gentlemen, thank you for standing by. My name is Abby, and I will be your conference operator today. At this time, I would like to welcome everyone to ACADIA Pharmaceuticals Second Quarter 2026 Earnings Conference Call. [Operator Instructions]
And I would now like to turn the conference over to Albert Kildani, Senior Vice President, Investor Relations and Corporate Development. Please go ahead.
Albert Kildani
Senior Vice President of Investor Relations & Corporate Communications
Good afternoon, and thank you for joining us on today's call to discuss ACADIA's second quarter 2026 financial results.
Joining me on the call today from ACADIA are Catherine Owen Adams, our Chief Executive Officer, who will provide some opening remarks; followed by Tom Garner, our Chief Commercial Officer, who will discuss our commercial brands, DAYBUE and NUPLAZID. Also joining us today
Acadia Pharmaceuticals vykázala za čtvrtletí zisk 0,18 USD na akcii a tržby 307,96 milionu USD, obojí nad odhady. Zisk byl také vyšší než 0,16 USD před rokem.
Acadia Pharmaceuticals (ACAD - Free Report) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.16 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +200.00%. A quarter ago, it was expected that this drugmaker would post earnings of $0.04 per share when it actually produced earnings of $0.02, delivering a surprise of -50%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
Acadia, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $307.96 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 4.81%. This compares to year-ago revenues of $264.57 million. The company has topped consensus revenue estimates two times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Acadia shares have lost about 4.1% since the beginning of the year versus the S&P 500's gain of 11%.
What's Next for Acadia?While Acadia has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Acadia was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.13 on $328.06 million in revenues for the coming quarter and $0.39 on $1.24 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 42% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the same industry, MaxCyte, Inc. (MXCT - Free Report) , is yet to report results for the quarter ended June 2026. The results are expected to be released on August 12.
This company is expected to post quarterly loss of $0.12 per share in its upcoming report, which represents no change from the year-ago quarter. The consensus EPS estimate for the quarter has been revised 14.3% lower over the last 30 days to the current level.
MaxCyte, Inc.'s revenues are expected to be $6.5 million, down 23.6% from the year-ago quarter.
Acadia Pharmaceuticals zvýšila celoroční výhled tržeb na 1,24 až 1,30 miliardy USD. Ve 2. čtvrtletí vzrostly tržby DAYBUE o 30 % meziročně na 125 milionů USD.
- Second quarter DAYBUE® GAAP net sales of $125 million, up 30% year-over-year driven by strong uptake of DAYBUE STIX
- Second quarter NUPLAZID® GAAP net sales of $183 million, up 10% year-over-year on a non-GAAP adjusted basis
- Increased full year 2026 total revenue guidance to $1.24 to $1.30 billion, reflecting higher DAYBUE guidance of $480 to $510 million and reaffirmed NUPLAZID guidance of $760 to $790 million
- Topline results from the Phase 2 remlifanserin study in Alzheimer’s disease psychosis anticipated September to October 2026
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the second quarter ended June 30, 2026.
“Acadia delivered an outstanding second quarter, highlighted by strong commercial execution across both DAYBUE and NUPLAZID, resulting in total revenue growth of 17% year-over-year on an adjusted basis,” said Catherine Owen Adams, Chief Executive Officer of Acadia. “For DAYBUE, continued patient demand and robust uptake of STIX drove another quarter of strong performance. For NUPLAZID, we continued to see strong momentum, especially in new-to-brand prescriptions as our recently expanded sales force gained traction in the field. We remain confident that both franchises are on track to achieve our long-term ambition of approximately $1.7 billion in annual net sales in 2028. Looking ahead, we are excited about the anticipated topline results from our Phase 2 program evaluating remlifanserin in Alzheimer's disease psychosis in the September to October timeframe, which we believe represents a potentially transformational opportunity for Acadia.”
Company Updates
Completed enrollment in the Phase 2 portion of the RADIANT program evaluating remlifanserin in Alzheimer's disease psychosis and initiated Phase 3 screening and enrollment; topline Phase 2 results are expected in September to October 2026. Received FDA Fast Track designation for remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer's disease psychosis, recognizing its potential to address a significant unmet medical need. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If approved by the European Commission, DAYBU would become the first authorized treatment for Rett syndrome in the European Union. Financial Results
Revenues
GAAP total revenues, comprised of net product sales from NUPLAZID and DAYBUE, were $308 million for the second quarter of 2026, up 16% as compared to GAAP total revenues of $265 million in the second quarter of 2025, and up 17% as compared to non-GAAP adjusted total revenues of $262 million in the second quarter of 2025.
GAAP net product sales of NUPLAZID were $183 million for the second quarter of 2026, up 9% compared to GAAP net product sales of $168 million for the second quarter of 2025, and up 10% as compared to non-GAAP adjusted net product sales of $166 million for the second quarter of 2025.
Net product sales of DAYBUE were $125 million for the second quarter of 2026, an increase of 30% as compared to $96 million for the second quarter of 2025.
A reconciliation of NUPLAZID non-GAAP adjusted net product sales and non-GAAP adjusted total revenues is provided in Table 1. A description of these adjustments is included under ‘Non-GAAP Financial Measures.’
Research and Development
Research and development expenses for the second quarter of 2026 were $82 million, compared to $78 million for the same period of 2025.
Selling, General and Administrative
Selling, general and administrative expenses for the second quarter of 2026 were $160 million, compared to $134 million for the same period of 2025.
Net Income
For the second quarter of 2026, Acadia reported net income of $32 million, or $0.18 per diluted share, compared to a net income of $27 million, or $0.16 per diluted share, for the same period in 2025.
Cash and Investments
At June 30, 2026, Acadia’s cash, cash equivalents, and investment securities totaled $956 million, compared to $820 million at December 31, 2025.
Full Year 2026 Financial Guidance (GAAP):
Acadia is updating its 2026 guidance:
Total revenues revised to a range of $1.24 to $1.30 billion, up from the previous range of $1.22 to $1.28 billion. NUPLAZID net product sales in the range of $760 to $790 million. DAYBUE (including all forms of trofinetide) global net product sales in the range of $480 to $510 million, up from the previous range of $460 to $490 million. R&D expense in the range of $355 to $380 million, down from the previous range of $385 to $410 million. SG&A expense in the range of $660 to $700 million. Conference Call and Webcast Information
Acadia will host a conference call to discuss the second quarter 2026 results today, Tuesday, August 4, 2026 at 1:30 p.m. PT/4:30 p.m. ET. The conference call may be accessed by registering for the call here. Once registered, participants will receive an email with the dial-in number and unique PIN number to use for accessing the call.
About NUPLAZID® (pimavanserin)
Pimavanserin is a selective serotonin inverse agonist and antagonist preferentially targeting 5-HT2A receptors. These receptors are thought to play an important role in neuropsychiatric disorders. In vitro, pimavanserin demonstrated no appreciable binding affinity for dopamine (including D2), histamine, muscarinic, or adrenergic receptors. Pimavanserin was approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis by the U.S. Food and Drug Administration in April 2016 under the trade name NUPLAZID.
About DAYBUE® (trofinetide)
Trofinetide is a synthetic version of a naturally occurring molecule known as the tripeptide glycine-proline-glutamate (GPE). The mechanism by which trofinetide exerts therapeutic effects in patients with Rett syndrome is unknown. Trofinetide was approved for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older by the U.S. Food and Drug Administration in March 2023 under the trade name DAYBUE or DAYBUE STIX.
About Acadia Pharmaceuticals
Acadia is committed to turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world. Our commercial portfolio includes the first and only FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome. We are developing the next wave of therapeutic advancements with a robust and diverse pipeline that includes mid- to late-stage programs in Alzheimer’s disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. At Acadia, we’re here to be their difference. For more information, visit us at acadia.com and follow us on LinkedIn and X.
Non-GAAP Financial Measures
This press release contains the following financial measures that do not comply with U.S. generally accepted accounting principles (GAAP): non-GAAP adjusted net product sales for NUPLAZID for the second quarter of 2025 and non-GAAP adjusted total revenues for the second quarter of 2025. In preparing these non-GAAP financial results, the Company includes adjustments made to reflect the impact of a change in estimate related to NUPLAZID IRA rebate accruals. Please refer to our press release dated February 25, 2026, for additional details. These non-GAAP financial measures complement GAAP results and are used by management to analyze financial performance and evaluate period-to-period changes. Management believes these non-GAAP financial measures are useful to investors and other users of the Company’s financial statements to facilitate period-to-period comparability. These non-GAAP financial measures are not meant to be considered as a substitute for comparable GAAP measures; should be read in conjunction with the Company’s consolidated financial statements prepared in accordance with GAAP; have no standardized meaning prescribed by GAAP; and are unlikely to be comparable with non-GAAP disclosures released by other companies.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements other than statements of historical fact and can be identified by terms such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “predicts,” “potential,” “guidance,” “continue” and similar expressions (including the negative thereof) intended to identify forward-looking statements. Forward-looking statements contained in this press release, include, but are not limited to, statements about: (i) our business strategy, objectives and opportunities, including support for and innovations in our pipeline assets and business development opportunities, sales growth for DAYBUE and uptake in DAYBUE STIX, and potential for enhanced shareholder value; (ii) the momentum and expectations for NUPLAZID with the expanded sales force, (iii) the FDA’s potential review of a new drug application for remlifanserin as a treatment for Alzheimer’s disease psychosis, (iv) the receipt and timing of the topline results of the RADIANT Phase 2 study, the transformational opportunity of those results, and the enrollment of the Phase 3 portion of the RADIANT development program, (v) potential approval of DAYBU (trofinetide) in the European Union, (vi) plans for, including timing, development and progress of commercialization or regulatory timelines for our products and our product candidates; (vii) benefits to be derived from and efficacy of our products, including the potential advantages of our products; and (viii) our estimates regarding our future financial performance, profitability, capital requirements or expenses, including our full year 2026 financial guidance and anticipated net product sales by the end of 2028. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. Such risks, uncertainties and other factors include, but are not limited to: our dependency on the continued successful commercialization of our products and our ability to maintain or increase sales of our products; the success of our plans to continue commercial growth; the costs of our commercialization plans and development programs, and the financial impact or revenues from any commercialization we undertake; our ability to obtain necessary regulatory approvals for our product candidates and, if and when approved, market acceptance of our products; the risks associated with clinical trials and their outcomes, including risks of unsuccessful enrollment and negative or inconsistent results; our dependence on third-party collaborators, clinical research organizations, manufacturers, suppliers and distributors; the impact of competitive products and therapies; our ability to generate or obtain the necessary capital to fund our operations; our ability to grow, equip and train our specialized sales forces; our ability to manage the growth and complexity of our organization; our ability to maintain, protect and enhance our intellectual property; and our ability to continue to stay in compliance with applicable laws and regulations. Given the risks and uncertainties, you should not place undue reliance on these forward-looking statements. For a discussion of these and other risks, uncertainties and other factors that may cause our actual results, performance or achievements to differ, please refer to our annual report on Form 10-K for the year ended December 31, 2025 as well as our subsequent filings with the Securities and Exchange Commission from time to time. The forward-looking statements contained herein are made as of the date hereof, and we undertake no obligation to update them after this date, except as required by law.
ACADIA PHARMACEUTICALS INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)
(Unaudited)
Three Months Ended June 30,
Six Months Ended June 30,
2026
2025
2026
2025
Revenues
Product sales, net
$
307,959
$
264,566
$
576,021
$
508,882
Total revenues
307,959
264,566
576,021
508,882
Operating expenses
Cost of product sales (1)(2)
28,316
20,734
53,107
41,126
Research and development (2)
81,555
77,951
158,423
156,216
Selling, general and administrative (2)
160,252
133,507
331,271
259,877
Total operating expenses
270,123
232,192
542,801
457,219
(Loss) income from operations
37,836
32,374
33,220
51,663
Interest income, net
7,990
7,243
16,045
15,144
Other income
647
594
1,189
1,183
Income before income taxes
46,473
40,211
50,454
67,990
Income tax expense
14,973
13,545
15,317
22,337
Net income
$
31,500
$
26,666
$
35,137
$
45,653
Earnings per share:
Basic
$
0.18
$
0.16
$
0.21
$
0.27
Diluted
$
0.18
$
0.16
$
0.20
$
0.27
Weighted average common shares outstanding:
Basic
171,603
167,827
171,063
167,321
Diluted
172,851
168,681
172,890
168,219
(1) Includes license fees and royalties
(2) Includes the following stock-based compensation expense
Acadia získala od FDA status Fast Track pro remlifanserin na halucinace a bludy spojené s psychózou při Alzheimerově chorobě. Topline data z fáze II čeká mezi zářím a říjnem 2026.
Key Takeaways Acadia received FDA Fast Track designation for remlifanserin in Alzheimer's disease psychosis. ACAD expects phase II top-line data between September and October 2026 as phase III enrollment continues. Acadia expects Nuplazid and Daybue combined net sales of about $1.7 billion by 2028. Acadia Pharmaceuticals (ACAD - Free Report) announced that the FDA has granted Fast Track designation to its investigational, highly selective, 5-HT2A receptor inverse agonist, remlifanserin, for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP).
The FDA’s Fast Track designation is intended to expedite the development and review of drugs that treat serious conditions and fulfill unmet medical needs to get important new drugs to patients earlier. It offers benefits, such as more frequent FDA interactions, rolling submission of marketing applications and potential eligibility for Priority Review if certain conditions are met.
According to Acadia, there are currently no FDA-approved therapies for treating ADP.
More on ACAD’s RemlifanserinClinical Development ProgramAcadia is currently evaluating the safety and efficacy of remlifanserin in the RADIANT development program for the treatment of hallucinations and delusions associated with ADP. The company has completed enrollment in the phase II portion of the program and now expects to report top-line results between September and October 2026. Meanwhile, in line with the RADIANT program's seamless operational design, screening and patient enrollment are already underway for the phase III studies. In 2025, ACAD initiated another phase II study of remlifanserin for a second indication – Lewy Body Dementia with Psychosis.
Year to date, ACAD shares have lost 6% against the industry’s 2.4% growth.
Image Source: Zacks Investment Research
Apart from remlifanserin, Acadia’s clinical pipeline comprises several other candidates. The company, in partnership with Saniona, is gearing up to initiate a mid-stage study of ACP-711 for essential tremor in late 2026. In late 2025, ACAD initiated a mid-stage study of ACP-211 for the treatment of major depressive disorder. A first-in-human study of ACP-271 in healthy volunteers was also initiated in the first quarter of 2026.
ACAD's Marketed Drugs Expected to Aid GrowthAcadia’s long-term growth is supported by its lead product, Nuplazid and Daybue, in the United States. The company expects to generate around $1.7 billion in combined net sales by 2028, including $1 billion for Nuplazid and $700 million for Daybue.
Nuplazid is the first and only FDA-approved treatment for hallucinations and delusions associated with Parkinson’s disease psychosis in the United States. The drug enjoys patent protection in the United States until 2038, giving it a long runway for revenue generation by protecting against generic erosion. In the first quarter of 2026, Nuplazid recorded $167 million in sales, up 5% year over year, driven primarily by volume growth.
Since its U.S. launch in 2023 as the first and only treatment for Rett syndrome in adults and pediatric patients aged two years and older, Daybue has witnessed encouraging sales uptake. In the first quarter of 2026, Daybue recorded $101 million in sales, up 20% year over year, driven by growth in the drug’s unit sales as Acadia shipped it to more unique patients. A similar filing is also currently under regulatory review in the EU. A potential nod could further boost sales. Daybue is also marketed (and available) in Canada and Israel for the same indication.
In late 2025, the FDA approved Daybue Stix (trofinetide), a dye- and preservative-free powder formulation for the treatment of Rett syndrome in adults and pediatric patients aged two years and older. The new product expands the Daybue franchise, which remains the only FDA-approved treatment option for this indication.
Daybue Stix is now broadly available in the United States. The company will continue to offer the current oral solution alongside the new formulation, strengthening its positioning in the Rett syndrome treatment market.
ACAD's Zacks Rank & Stocks to ConsiderAcadia currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Neurocrine Biosciences (NBIX - Free Report) , Amarin Corporation (AMRN - Free Report) and Liquidia Corporation (LQDA - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Neurocrine Biosciences’ 2026 earnings per share have risen from $9.15 to $9.44. Over the same period, EPS estimates for 2027 have increased from $10.23 to $10.79. NBIX shares have gained 22% year to date.
Neurocrine Biosciences’ earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 9.08%.
Over the past 60 days, loss per share estimates for Amarin have narrowed from $6.36 to 65 cents for 2026. Over the same period, estimates for loss per share have also narrowed from $4.64 to 51 cents for 2027. AMRN shares have lost 2.5% year to date.
Amarin’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 50.02%.
Over the past 60 days, estimates for Liquidia’s 2026 earnings per share have increased to $3.02 from $2.97. Over the same period, EPS estimates for 2027 have risen to $4.92 from $4.81. LQDA shares have soared 123.5% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 54.40%.
Insider společnosti Acadia Pharmaceuticals James Kihara prodal 11 421 akcií, tedy 46,6 % svých přímých podílů, za zhruba 298 000 USD. Prodej proběhl v rámci předem daného plánu Rule 10b5-1.
James Kihara, Principal Accounting Officer of Acadia Pharmaceuticals (ACAD 0.72%), disclosed the sale of 11,421 shares of common stock in an open-market transaction on June 26, 2026, according to the SEC Form 4 filing.
Transaction summaryMetricValueShares sold (direct)11,421Transaction value~$298,000Post-transaction shares (direct)13,088Post-transaction value (direct ownership)~$331,000Transaction value based on SEC Form 4 weighted average price ($26.08); post-transaction value based on June 26, 2026 market close price.
Key questionsHow does this transaction compare to prior open-market sales by James Kihara?
This 11,421-share sale is Kihara's largest single open-market sale on record, exceeding his previous sale on May 26, 2026 (5,401 shares), and surpassing the five-trade average of approximately 4,964 shares per sale.What proportion of Kihara's available direct shareholding was involved in this sale?
The transaction represented 46.60% of his direct holdings prior to the sale, a significant reduction that left only 13,088 shares directly held post-transaction.Were any derivative or indirect holdings involved in this disposition?
No derivative securities or indirect entities were involved; all shares sold were directly owned common stock, and no options or trust-held shares were reported in this filing.Does the cadence or scale of this sale reflect a change in disposition strategy?
Recent filings indicate an acceleration in selling as Kihara’s holdings have declined, with increasing sale sizes explained by the drawdown in available capacity rather than a discretionary slow-down or escalation.Company overviewMetricValueEmployees653Revenue (TTM)$1.10 billionNet income (TTM)$375.65 million1-year price change23.96%*1-year price change calculated as of June 26, 2026.
Company snapshotCore product: NUPLAZID (pimavanserin) for Parkinson's disease psychosis; pipeline includes late-stage candidates for Alzheimer's disease psychosis, Rett syndrome, and pain management.Revenue is primarily generated through the commercialization of proprietary therapeutics for central nervous system (CNS) disorders, with additional growth potential from clinical-stage assets.Target customers include neurologists, psychiatrists, and healthcare providers treating CNS disorders, with a focus on patients experiencing unmet medical needs.Acadia Pharmaceuticals is a biopharmaceutical company specializing in the discovery, development, and commercialization of innovative treatments for central nervous system disorders.
The company leverages its expertise in neuroscience to address significant gaps in the treatment landscape, with a marketed product and several late-stage pipeline candidates. Acadia’s strategic focus on high-need indications and a robust clinical pipeline position it as a differentiated player within the biotechnology sector.
What this transaction means for investorsThe June 26 sale of Acadia Pharmaceuticals stock by Principal Accounting Officer James Kihara is noteworthy for investors because it represented a substantial disposition of 46.6% of his holdings. The transaction came at a time when Acadia shares were soaring on the news that the European Medicines Agency recommended the company’s Daybue drug be allowed for sale in the European Union.
Kihara’s trade was at a weighted average price of $26.08 per share, close to the 52-week high of $28.35. While it seems he was capitalizing on the rising price, his sale was a non-discretionary transaction executed as part of a pre-established Rule 10b5-1 plan, adopted in December of 2025. Such plans enable insiders to sell shares at predetermined times to avoid concerns of trading on non-public information.
Even so, the fact that he disposed of nearly half his direct holdings is concerning, especially since the sale was about double his average transaction size. However, Acadia’s business is doing well. It kicked off 2026 with $268.1 million in first-quarter revenue, up from the prior year’s $244.3 million.
Robert Izquierdo has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
ACAD vzrostla o 6,8 % poté, co CHMP doporučil schválení Daybu v EU pro léčbu neurobehaviorálních příznaků Rettova syndromu u dospělých a pediatrických pacientů od 5 let věku. Pokud projde, půjde o první takovou terapii v EU.
Key Takeaways ACAD up 6.8% after the CHMP recommended Daybu for EU approval in Rett syndrome following re-examination.Daybu could become the first EU-approved treatment for Rett syndrome's neurobehavioral symptoms.Acadia's phase III LAVENDER data supported the positive opinion after an earlier CHMP refusal. Acadia Pharmaceuticals (ACAD - Free Report) shares climbed 6.8% on Friday after the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion following a re-examination procedure, recommending the approval of Daybu (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. The recommendation marks a major regulatory turnaround for the therapy, which could become the first approved treatment for this indication in the EU.
The positive CHMP recommendation represents an important milestone for Acadia as it seeks to expand Daybu's commercial footprint. Rett syndrome is a rare neurodevelopmental disorder with no therapies currently approved in the EU specifically for its neurobehavioral symptoms, leaving patients with limited treatment options. An approval would allow Acadia to address a significant unmet medical need while strengthening the long-term growth prospects of its rare disease franchise.
The CHMP's favorable opinion was primarily supported by data from the pivotal phase III LAVENDER study, which demonstrated statistically significant and clinically meaningful improvements in key measures of Rett syndrome. The study met its co-primary endpoints, showing benefits on the Rett Syndrome Behavior Questionnaire and the Clinical Global Impression-Improvement scale, indicating that Daybu can improve some of the core neurobehavioral manifestations of the disease that substantially affect patients' daily functioning and caregiver burden.
Following the CHMP recommendation, the European Commission (EC) will review the agency's opinion before issuing a final regulatory decision, which is expected in the coming months. If approved, Daybu's centralized marketing authorization would be valid across all 27 EU member states as well as Iceland, Liechtenstein and Norway, significantly expanding access to the therapy across Europe.
The FDA approved trofinetide as the first and only treatment for Rett syndrome in adults and pediatric patients aged two years and older in 2023. The drug is marketed under the brand name Daybue in the United States. Daybue is also marketed (and available) in Canada and Israel for the same indication.
Year to date, Acadia shares have lost 5.2% against the industry’s 5.2% growth.
Image Source: Zacks Investment Research
Earlier CHMP Refusal Delayed EU Expansion of ACAD’s DaybuThe latest recommendation follows a significant regulatory setback earlier this year, when the CHMP formally adopted a negative opinion recommending against the approval of trofinetide for the treatment of Rett syndrome in patients aged two years and older in the EU. The decision came after the committee had previously notified Acadia of a negative trend vote on the marketing application in early February, prompting the company to seek a formal re-examination of the application.
Although the pivotal LAVENDER study had achieved its co-primary and key secondary endpoints, the CHMP had previously concluded that several aspects of the evidence package limited its ability to support approval. The committee viewed the treatment benefit observed after 12 weeks as modest, questioned whether the study adequately captured all core symptoms of Rett syndrome and expressed concerns that patient discontinuations may have affected the interpretation of longer-term outcomes.
Following the initial refusal, Acadia reviewed the CHMP's objections in detail and proceeded with the re-examination process, ultimately securing the positive recommendation now under consideration by the EC. The favorable outcome substantially improves the therapy's regulatory outlook in Europe and revives the company's efforts to bring Daybu to patients across the region.
ACAD's Marketed Drugs Expected to Aid GrowthAcadia’s long-term growth is supported by its lead product, Nuplazid and Daybue in the United States. The company expects to generate around $1.7 billion in combined net sales by 2028, including $1 billion for Nuplazid and $700 million for Daybue.
Nuplazid is the first and only FDA-approved treatment for hallucinations and delusions associated with Parkinson’s disease psychosis in the United States. The drug enjoys patent protection in the United States until 2038, which gives it a long runway for revenue generation by protecting against generic erosion. In the first quarter of 2026, Nuplazid recorded $167 million in sales, up 5% year over year, driven primarily by volume growth.
Since its launch in 2023, Daybue has witnessed encouraging sales uptake. In the first quarter of 2026, Daybue recorded $101 million in sales, up 20% year over year, driven by growth in the drug’s unit sales as Acadia shipped it to more unique patients. A potential EU approval could further boost sales.
In late 2025, the FDA approved Daybue Stix (trofinetide) for oral solution, a dye- and preservative-free powder formulation for the treatment of Rett syndrome in adults and pediatric patients aged two years and older. The new product expands the Daybue franchise, which remains the only FDA-approved treatment option for this indication.
Per Acadia, the full U.S. launch of Daybue STIX is underway, with nearly 30% of patients using STIX either new to treatment or resuming therapy after previously discontinuing the liquid formulation. The company will continue to offer both formulations in the United States, strengthening its positioning in the Rett syndrome treatment market.
ACAD's Zacks Rank & Stocks to ConsiderAcadia currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Liquidia Corporation (LQDA - Free Report) , Indivior Pharmaceuticals (INDV - Free Report) and Immunocore (IMCR - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Liquidia Corporation’s 2026 EPS have increased from $1.50 to $2.97. Over the same period, EPS estimates for 2027 have also increased from $2.91 to $4.81. LQDA shares have rallied 126.7% year to date.
Liquidia Corporation’searnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 54.40%.
Over the past 60 days, estimates for Indivior Pharmaceuticals’ 2026 earnings per share have increased from $3.34 to $4.05. Over the same period, EPS estimates for 2027 have risen to $4.27 from $3.56. INDV shares have gained 16.6% year to date.
Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 65.44%.
The estimate for Immunocore’s 2026 EPS is currently pegged at 6 cents. In the past 60 days, the estimates for its 2027 EPS have increased from 24 cents to 87 cents. IMCR shares have lost 11% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 46.66%.
Akcie Acadia Pharmaceuticals v pátek vyskočily poté, co evropští regulátoři nečekaně otočili své dřívější rozhodnutí a doporučili schválení léku Daybue na Rettův syndrom.
Founder's ClubSwingTraderLeaderboardMarketSurgeeIBDIBD DigitalIBD LiveCustomer Center
My Stock Lists
Email Preferences
Help & Support
Sign Out
Search stocks or keywords
Sections
My IBD
MARKET TREND
STOCK LISTS
STOCK RESEARCH
NEWSECONOMY
VIDEOS & PODCASTS
HOW TO INVESTEDUCATIONAL RESOURCESStoreMy Products
Founder's ClubSwingTraderLeaderboardMarketSurgeeIBDIBD DigitalIBD Live
Recently Searched
Flash Memory Chipmaker Sandisk Hits Record High, Leads 18 Onto Best Growth Stock Lists
OpenAI Mulls Delaying IPO Until 2027: Report
Nasdaq Extends Losing Streak Even As Micron Soars On Earnings; Apple Stock Dives Below Key Level Acadia stock popped Friday after European regulators unexpectedly reversed a previous decision, saying they would, in fact, recommend approval of the company's Rett syndrome drug, Daybu. Rett syndrome is a rare, neurological condition that affects primarily females. It causes progressive loss of purposeful hand use, language and motor coordination. Acadia Pharmaceuticals (ACAD) sells its drug under the brand Daybue in…
